Stock listing
NASDAQ:IMNM Immunome, Inc. Stock
Home listing (NASDAQ) of Immunome, Inc.
Follow Immunome, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:IMNM
$15.69 USD -1.09 (-6.5%)
Close on Nov 20, 2026
- Day range
- $15.55 – $16.73 USDNov 20, 2026
- Volume
- 1.06M sharesNov 20, 2026
- Market cap
- $1.85B USDAt the close on Nov 20, 2026 · price × 118.1M shares outstanding
- 52-week range
- $15.55 – $30.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $28.67M USDMedian day 1.17M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:IMNM · Home | $15.69 USD | -1.09 (-6.5%) | 1,056,097 | $16.45 | $16.73 | $15.55 | $16.78 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMNM · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.69 | -1.09 | -6.5% | $16.45 | $16.73 | $15.55 | 1,056,097 | |
| $16.78 | -0.40 | -2.3% | $17.16 | $17.89 | $16.65 | 1,412,326 | |
| $17.18 | -0.43 | -2.4% | $17.67 | $18.16 | $16.78 | 1,027,498 | |
| $17.61 | -1.16 | -6.2% | $18.50 | $19.15 | $17.55 | 1,518,971 | |
| $18.77 | +0.07 | +0.4% | $18.62 | $18.81 | $18.10 | 951,066 | |
| $18.70 | -0.37 | -1.9% | $18.74 | $19.06 | $18.02 | 1,658,580 | |
| $19.07 | +0.42 | +2.3% | $18.81 | $19.29 | $18.71 | 872,891 | |
| $18.65 | -0.71 | -3.7% | $18.11 | $19.13 | $18.11 | 1,253,489 | |
| $19.36 | +0.65 | +3.5% | $18.90 | $19.79 | $18.46 | 1,376,706 | |
| $18.71 | +0.805 | +4.5% | $18.21 | $18.95 | $17.32 | 1,330,509 | |
| $17.91 | -1.615 | -8.3% | $19.38 | $19.41 | $17.29 | 2,206,706 | |
| $19.52 | -0.79 | -3.9% | $20.64 | $22.77 | $18.47 | 3,321,760 | |
| $20.31 | +0.72 | +3.7% | $19.81 | $20.43 | $19.78 | 1,853,935 | |
| $19.59 | +1.38 | +7.6% | $18.42 | $19.77 | $18.40 | 2,282,696 | |
| $18.21 | -0.08 | -0.4% | $18.25 | $18.98 | $17.82 | 1,270,371 | |
| $18.29 | -0.47 | -2.5% | $18.88 | $19.30 | $18.11 | 877,800 | |
| $18.76 | -0.01 | -0.1% | $18.50 | $18.91 | $18.25 | 952,015 | |
| $18.77 | +0.88 | +4.9% | $17.95 | $19.00 | $17.50 | 1,225,654 | |
| $17.89 | -0.10 | -0.6% | $17.99 | $18.35 | $17.70 | 910,525 | |
| $17.99 | -0.27 | -1.5% | $18.13 | $18.25 | $17.65 | 1,378,899 | |
| $18.26 | +0.26 | +1.4% | $17.78 | $18.30 | $17.59 | 1,761,590 | |
| $18.00 | +0.08 | +0.4% | $17.99 | $18.44 | $17.85 | 1,545,126 | |
| $17.92 | +1.15 | +6.9% | $16.74 | $18.27 | $16.55 | 2,029,591 | |
| $16.77 | +0.30 | +1.8% | $16.60 | $16.92 | $16.44 | 1,139,956 | |
| $16.47 | -0.93 | -5.3% | $17.40 | $17.40 | $16.41 | 1,297,600 | |
| $17.40 | +0.20 | +1.2% | $17.31 | $17.61 | $17.08 | 1,621,100 | |
| $17.20 | -0.38 | -2.2% | $17.35 | $18.05 | $17.13 | 1,154,900 | |
| $17.58 | -1.57 | -8.2% | $19.06 | $19.16 | $17.43 | 2,198,600 | |
| $19.15 | -0.40 | -2.0% | $19.42 | $19.73 | $19.08 | 835,700 | |
| $19.55 | +0.24 | +1.2% | $19.05 | $19.72 | $18.88 | 998,000 | |
| $19.31 | +0.215 | +1.1% | $18.88 | $19.35 | $18.52 | 2,131,000 | |
| $19.10 | -0.215 | -1.1% | $18.94 | $19.56 | $18.94 | 1,161,000 | |
| $19.31 | -1.86 | -8.8% | $21.35 | $21.43 | $18.92 | 2,310,800 | |
| $21.17 | +0.27 | +1.3% | $20.79 | $21.48 | $20.67 | 1,216,200 | |
| $20.90 | +0.01 | 0.0% | $21.33 | $21.46 | $20.82 | 1,171,600 | |
| $20.89 | -0.62 | -2.9% | $21.17 | $21.49 | $20.71 | 1,096,800 | |
| $21.51 | -0.38 | -1.7% | $22.15 | $22.56 | $21.51 | 1,306,000 | |
| $21.89 | +0.21 | +1.0% | $21.64 | $22.01 | $21.36 | 917,000 | |
| $21.68 | +0.27 | +1.3% | $21.24 | $21.81 | $20.85 | 945,200 | |
| $21.41 | -0.93 | -4.2% | $22.43 | $22.65 | $21.15 | 2,421,600 | |
| $22.34 | -1.90 | -7.8% | $24.24 | $24.34 | $22.21 | 2,697,400 | |
| $24.24 | -1.51 | -5.9% | $25.88 | $25.94 | $24.04 | 2,270,600 | |
| $25.75 | +0.68 | +2.7% | $25.17 | $25.81 | $25.09 | 1,064,500 | |
| $25.07 | +1.10 | +4.6% | $24.63 | $25.26 | $24.19 | 1,180,500 | |
| $23.97 | +0.04 | +0.2% | $24.01 | $24.24 | $23.36 | 3,962,500 | |
| $23.93 | +0.47 | +2.0% | $24.10 | $24.64 | $23.77 | 890,800 | |
| $23.46 | -0.49 | -2.0% | $24.29 | $24.75 | $23.36 | 1,317,800 | |
| $23.95 | -0.60 | -2.4% | $24.44 | $24.48 | $23.55 | 1,332,000 | |
| $24.55 | -0.12 | -0.5% | $24.65 | $25.26 | $24.40 | 744,600 | |
| $24.67 | -0.30 | -1.2% | $25.32 | $25.73 | $24.60 | 692,600 | |
| $24.97 | -1.15 | -4.4% | $25.69 | $26.08 | $24.91 | 729,900 | |
| $26.12 | -0.69 | -2.6% | $26.43 | $26.99 | $26.10 | 784,100 | |
| $26.81 | +0.05 | +0.2% | $26.15 | $27.25 | $25.91 | 828,600 | |
| $26.76 | -0.40 | -1.5% | $26.68 | $27.14 | $26.66 | 562,300 | |
| $27.16 | -0.17 | -0.6% | $27.60 | $28.27 | $26.67 | 796,100 | |
| $27.33 | +0.265 | +1.0% | $27.56 | $28.49 | $26.81 | 811,100 | |
| $27.07 | -0.345 | -1.3% | $27.23 | $27.31 | $26.64 | 700,200 | |
| $27.41 | -0.16 | -0.6% | $27.48 | $27.63 | $27.00 | 1,050,700 | |
| $27.57 | -1.30 | -4.5% | $28.45 | $28.77 | $27.40 | 783,500 | |
| $28.87 | +0.12 | +0.4% | $28.57 | $29.11 | $28.35 | 1,055,500 | |
| $28.75 | -0.635 | -2.2% | $29.34 | $29.39 | $28.62 | 558,800 | |
| $29.39 | +1.375 | +4.9% | $27.88 | $29.72 | $27.88 | 1,928,300 | |
| $28.01 | -0.51 | -1.8% | $28.48 | $28.85 | $27.64 | 1,355,400 | |
| $28.52 | +0.44 | +1.6% | $28.46 | $29.30 | $28.13 | 846,500 | |
| $28.08 | -1.745 | -5.9% | $29.13 | $29.15 | $27.89 | 1,025,500 |
- Ticker
- NASDAQ:IMNM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Immunome to Present at Upcoming Investor Conferences
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 33 slides
Latest news
Immunome to Present at Upcoming Investor Conferences
Nov 18, 2026
Closed $16.78 (-2.3%) on Nov 18, 2026
Immunome Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 9, 2026
Closed $18.65 (-3.7%) on Nov 10, 2026
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 6, 2026
Closed $19.36 (+3.5%) on Nov 9, 2026
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
Nov 4, 2026
Closed $19.52 (-3.9%) on Nov 4, 2026
Immunome to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 2, 2026
Closed $19.59 (+7.6%) on Nov 2, 2026
Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
Oct 30, 2026
Closed $18.21 (-0.4%) on Oct 30, 2026
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Oct 26, 2026
Closed $17.89 (-0.6%) on Oct 26, 2026
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Sep 30, 2026
Closed $21.51 (-1.7%) on Sep 30, 2026
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026
Closed $27.33 (+1.0%) on Sep 2, 2026
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 11, 2026
Closed $27.99 (+6.6%) on Aug 12, 2026
Immunome, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 30 in the last 12 months · 135 in all · newest Nov 18, 2026 · oldest 2020
- Decks
- 37 decks · latest October 2026
Where Immunome, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:IMNM · Home listing · This page | NASDAQ | United States | USD |
| BOATS:IMNM | BOATS | United States | USD |
Valuation
Price/book 4.1× against a median of 4.9×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.40B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.49
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immunome, Inc. · NASDAQ:IMNM | US$1.85B | US$1.40B | n/a | n/a | n/a | 4.1× | n/a | 0.0× | 1.49 |
| Shanghai Henlius Biotech, Inc. Class H · HKEX:2696 | US$1.91B | US$2.36B | 14.7× | 2.1× | 12.3× | 2.8× | 11.7% | 0.9× | n/a |
| Trevi Therapeutics, Inc. · NASDAQ:TRVI | US$1.90B | US$1.60B | n/a | n/a | n/a | 6.3× | n/a | 0.0× | 1.22 |
| Biohaven Ltd. · NYSE:BHVN | US$1.87B | US$1.71B | n/a | n/a | n/a | n/a | n/a | n/a | 1.19 |
| BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX | US$1.86B | US$1.88B | n/a | 1.9× | n/a | n/a | −37.4% | n/a | 0.62 |
| Zymeworks Inc. · NASDAQ:ZYME | US$1.84B | US$2.08B | 42.5× | 7.8× | 40.6× | 7.1× | 16.3% | 1.3× | 0.69 |
| Vera Therapeutics, Inc. · NASDAQ:VERA | US$1.84B | US$1.53B | n/a | 149× | n/a | 5.5× | n/a | 0.2× | 1.13 |
| Hemab Therapeutics Holdings, Inc. · NASDAQ:COAG | US$1.84B | US$1.41B | n/a | n/a | n/a | 4.3× | n/a | 0.0× | 0.61 |
| Braveheart Bio, Inc. · NASDAQ:BRVE | US$1.84B | US$1.71B | n/a | n/a | n/a | 3.7× | n/a | 0.0× | n/a |
| Septerna, Inc. · NASDAQ:SEPN | US$1.84B | US$1.38B | n/a | 14.3× | n/a | 4.3× | −61.3% | 0.1× | 0.95 |
| Replimune Group, Inc. · NASDAQ:REPL | US$1.81B | US$1.60B | n/a | n/a | n/a | 8.8× | n/a | 0.5× | 0.78 |
| Median of the others | US$1.84B | US$1.66B | 28.6× | 7.8× | 26.5× | 4.9× | −12.9% | 0.1× | 0.87 |
Forecasts
13 strong buy · 3 buy · 1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 35.20 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.47 · 13 analysts
- Revenue, year to Dec 2026
- 500K · 8 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Clay Siegall | President & Chief Executive Officer |
| Max Rosett | Chief Financial Officer |
| Sandra Stoneman | Chief Legal Officer and Corporate Secretary |
| Roee Shahar | EVP, Commercial |
| Bob Lechleider | Chief Medical Officer |
| Jack Higgins | Chief Scientific Officer |
| Phil Tsai | Chief Technical Officer |
Board
| Director | Role |
|---|---|
| Isaac Barchas | Lead Independent Director and Director |
| James Boylan | Director |
| Sandra M. Swain | Director |
Events
- Next results
- Mar 3, 2027 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · After close | −3.7% |
| Q2 2026 | Aug 11, 2026 · After close | +6.6% |
| Q1 2026 | May 7, 2026 | −3.6% |
| Q4 2025 | Mar 3, 2026 · After close | +4.5% |
| Q3 2025 | Nov 6, 2025 · After close | −1.7% |
| Q2 2025 | Aug 6, 2025 · After close | −5.6% |
| Q1 2025 | May 12, 2025 · After close | −0.4% |
| Q4 2024 | Mar 19, 2025 | +3.6% |
| Q3 2024 | Nov 13, 2024 · After close | −3.9% |
| Q2 2024 | Aug 12, 2024 · After close | +7.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −5.7% |
| Q4 2023 | Mar 28, 2024 · After close | −10.4% |
| Q3 2023 | Nov 9, 2023 · Before open | −2.7% |
| Q2 2023 | Aug 9, 2023 · Before open | −2.1% |
| Q1 2023 | May 5, 2023 · Before open | −4.1% |
| Q4 2022 | Mar 16, 2023 · Before open | +9.2% |
| Q3 2022 | Nov 14, 2022 · Before open | +0.6% |
| Q2 2022 | Aug 5, 2022 · Before open | +17.4% |
| Q1 2022 | May 12, 2022 · Before open | +10.4% |
| Q4 2021 | Mar 28, 2022 · Before open | +23.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 33 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 32 slides | September 2026 |
| Investor Presentation (September 2026) | Investor deck | 33 slides | September 2026 |
| 2026 American Society of Clinical Oncology (ASCO) Annual Meeting | Conference | 14 slides | Jun 2, 2026 |
| Investor Presentation (May 2026) | Investor deck | 32 slides | May 2026 |
| Investor Presentation (April 2026) | Investor deck | 31 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 32 slides | March 2026 |
| 44th Annual J.P. Morgan Healthcare Conference (January 2026) | Conference | 32 slides | January 2026 |
| Corporate Update (December 2025) | Corporate update | 24 slides | Dec 15, 2025 |
| Investor Presentation (December 2025) | Investor deck | 32 slides | Dec 15, 2025 |
All 37 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2025) | Investor deck | 38 slides | November 2025 |
| Investor Presentation (September 2025) | Investor deck | 36 slides | September 2025 |
| ASCO 2025 | Conference | 11 slides | June 2025 |
| Investor Presentation (April 2025) | Investor deck | 35 slides | April 2025 |
| Investor Presentation (March 2025) | Investor deck | 35 slides | March 2025 |
| Investor Presentation (August 2024) | Investor deck | 36 slides | Aug 13, 2024 |
| Investor Presentation (July 2024) | Investor deck | 40 slides | July 2024 |
| Investor Presentation (May 2024) | Investor deck | 40 slides | May 2024 |
| Investor Presentation (February 2024) | Investor deck | 40 slides | Feb 8, 2024 |
| Investor Presentation (January 2024) | Investor deck | 35 slides | Jan 11, 2024 |
| Investor Presentation (November 2023) | Investor deck | 27 slides | Nov 15, 2023 |
| Investor Presentation (November 2023) | Investor deck | 26 slides | Nov 15, 2023 |
| Investor Presentation (November 2023) | Investor deck | 27 slides | Nov 15, 2023 |
| Merger or Acquisition (July 2023) | Merger or acquisition | 27 slides | July 2023 |
| Merger or Acquisition (June 2023) | Merger or acquisition | 27 slides | Jun 29, 2023 |
| Investor Presentation (January 2023) | Investor deck | 27 slides | Jan 30, 2023 |
| Investor Presentation (January 2023) | Investor deck | 34 slides | January 2023 |
| Investor Presentation (November 2022) | Investor deck | 35 slides | Nov 15, 2022 |
| Investor Presentation (June 2022) | Investor deck | 31 slides | Jun 9, 2022 |
| Investor Presentation (February 2022) | Investor deck | 38 slides | Feb 8, 2022 |
| Investor Presentation (October 2021) | Investor deck | 34 slides | Oct 18, 2021 |
| Investor Presentation (September 2021) | Investor deck | 32 slides | Sep 21, 2021 |
| Investor Presentation (July 2021) | Investor deck | 30 slides | Jul 20, 2021 |
| Investor Presentation (April 2021) | Investor deck | 38 slides | Apr 26, 2021 |
| Investor Presentation (March 2021) | Investor deck | 30 slides | Mar 29, 2021 |
| Investor Presentation (March 2021) | Investor deck | 29 slides | Mar 16, 2021 |
| Investor Presentation (October 2020) | Investor deck | 33 slides | Oct 26, 2020 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Update: about US$400M · US$21.5 a share · Leerink Partners +6 Dealers: Leerink Partners (lead), J.P. Morgan (lead), TD Cowen (lead), Goldman Sachs & Co. LLC (lead), Guggenheim Securities (lead), Wedbush PacGrow (co-lead), LifeSci Capital (co-lead) | Dec 16, 2025 |
| Public offering of common stock Closed: US$172.5M raised · US$7.75 a share · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), TD Cowen (co-lead), Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wedbush PacGrow | Jan 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$12.00 a share on Oct 1, 2020.
- Price
- US$12.00 a share
- Shares offered
- 3,250,000 shares of common stock
- Offering size
- US$39 million
- Underwriters' option
- Up to 487,500 more shares
- Listing
- IMNM on the Nasdaq Capital Market
- Underwriters
- Ladenburg Thalmann, Chardan · In the order on the cover
- Shares delivered
- On or about Oct 6, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 12, 2020 |
| Filed publicly | Sep 9, 2020 |
| Amended once | Sep 24, 2020 |
| Shares registered with an exchange | Sep 30, 2020 |
| Declared effective by the SEC | Oct 1, 2020 |
| Final prospectus, with the price | Oct 5, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 5, 2020 |
| EFFECT · Notice that a registration is effective | Oct 1, 2020 |
| S-1MEF · Registration of more shares for the same offering | Oct 1, 2020 |
| CERT · Exchange's certificate of listing | Oct 1, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 30, 2020 |
| CORRESP · Letter to the SEC | Sep 29, 2020 |
| CORRESP · Letter to the SEC | Sep 29, 2020 |
| S-1/A · Registration statement, amended | Sep 24, 2020 |
| CORRESP · Letter to the SEC | Sep 9, 2020 |
| S-1 · Registration statement | Sep 9, 2020 |
All 12 filings
| Filing | Filed |
|---|---|
| UPLOAD · Letter from the SEC | Sep 1, 2020 |
| DRS · Draft registration statement | Aug 12, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 5, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.94M | 9.04M | 14.0M | 6.63M | 0 | 0 | 0 | 0 |
| Cost of revenue | 2.96M | 2.10M | 728.0K | 631.0K | 755.0K | 755.0K | 615.0K | 521.0K |
| Gross profit | 3.99M | 9.04M | 14.0M | -631.0K | -755.0K | -755.0K | -615.0K | -521.0K |
| Research and development | 177.3M | 129.5M | 23.1M | 23.3M | 14.1M | 7.49M | 8.82M | 6.88M |
| Selling, general and administrative | 43.8M | 33.0M | 19.7M | 13.6M | 11.1M | 4.78M | 1.52M | 866.0K |
| Operating income | -224.1M | -305.8M | -109.5M | -36.9M | -25.2M | -12.3M | -10.3M | -7.74M |
| Depreciation and amortization | 2.47M | 1.57M | 457.0K | 422.0K | 755.0K | 755.0K | 615.0K | 521.0K |
| EBITDA | -221.6M | -304.2M | -109.1M | -36.5M | -24.4M | -11.5M | -9.73M | -7.22M |
| Interest expense | 5.00K | 10.0K | 21.0K | 46.0K | 141.0K | |||
| Income before tax | -212.4M | -293.0M | -106.8M | -36.9M | -24.7M | -17.8M | -10.4M | -7.84M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.0K |
| Net income | -212.4M | -293.0M | -106.8M | -36.9M | -24.7M | -17.8M | -10.4M | -7.84M |
| Earnings per share, basic | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | -7.18 |
| Earnings per share, diluted | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 653.5M | 143.4M | 98.7M | 20.3M | 49.2M | 39.8M | 2.54M | 1.60M |
| Short-term investments | 0 | 74.0M | 39.5M | 0 | ||||
| Receivables | 289.0K | 847.0K | 4.31M | 850.0K | ||||
| Inventory | -847.0K | -4.31M | -900.0K | |||||
| Current assets | 660.8M | 221.3M | 144.7M | 22.6M | 56.6M | 42.9M | 3.12M | 2.11M |
| Property, plant and equipment | 14.6M | 10.1M | 2.07M | 681.0K | 855.0K | 1.53M | 1.70M | 2.08M |
| Total assets | 683.2M | 240.2M | 148.5M | 24.0M | 57.9M | 44.5M | 5.06M | 4.45M |
| Accounts payable | 3.34M | 14.2M | 3.31M | 2.40M | 3.08M | 1.19M | 548.0K | 473.0K |
| Current liabilities | 45.0M | 54.3M | 21.8M | 7.33M | 9.73M | 3.04M | 1.67M | 1.56M |
| Long-term debt | 134.0K | 113.0K | 325.0K | |||||
| Total debt | 3.85M | 4.83M | 1.65M | 291.0K | 317.0K | 500.0K | 564.0K | 1.18M |
| Total liabilities | 48.8M | 59.1M | 28.7M | 7.39M | 9.74M | 3.18M | 1.80M | 29.7M |
| Shareholders' equity | 634.3M | 181.2M | 119.9M | 16.7M | 48.2M | 41.3M | -35.6M | -25.2M |
| Shares outstanding | 113.1M | 64.5M | 43.3M | 12.1M | 12.1M | 10.6M | 1.10M | 1.09M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -190.9M | -110.8M | -7.57M | -28.7M | -18.2M | -12.1M | -9.60M | -7.41M |
| Capital spending | -9.69M | -7.17M | -831.0K | -248.0K | -79.0K | -586.0K | -233.0K | -228.0K |
| Free cash flow | -200.6M | -118.0M | -8.40M | -28.9M | -18.3M | -12.7M | -9.83M | -7.63M |
| Cash from investing | 60.8M | -85.1M | -30.5M | -248.0K | -79.0K | -586.0K | -233.0K | -228.0K |
| Cash from financing | 640.4M | 240.5M | 116.4M | 32.0K | 27.8M | 49.9M | 10.8M | -551.0K |
| Dividends paid | -49.0K | -4.62M | ||||||
| Share buybacks | 32.0K | -49.0K | -35.0K | 0 | ||||
| Change in cash | 510.2M | 44.7M | 78.4M | -28.9M | 9.46M | 37.2M | 941.0K | -8.19M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Nov 9, 2026 | Offer document | SEC |
| S-3ASR · Registration statement | Nov 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Oct 5, 2026 | Material contract | SEC |
| 4 · Change in ownership | Sep 15, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 12, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 11, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 15, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 144/A · Notice of proposed sale, amended | Apr 3, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 2, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 23, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 12, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 3, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 3, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 3, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 17, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Dec 15, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 15, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 7, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 24, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 24, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 24, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 28, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 19, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 19, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 3, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jan 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jan 29, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2025 | Results | SEC |
| 8-K · Current report | Jan 23, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2024 | Insider trade | SEC |
| S-3ASR · Registration statement | Nov 22, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 29, 2024 | Acquisition or disposal | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| S-3ASR · Registration statement | Oct 8, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 7, 2024 | Current report | SEC |
| 4 · Change in ownership | Sep 20, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 19, 2024 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 21, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 17, 2024 | Insider trade | SEC |
| 424B5 · Prospectus | May 14, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 8-K · Current report | Apr 30, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Apr 29, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 29, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2024 | Management or board change | SEC |
| S-3ASR · Registration statement | Apr 3, 2024 | Offer document | SEC |
| S-3ASR · Registration statement | Apr 3, 2024 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 28, 2024 | Results | SEC |
| 8-K · Current report | Mar 26, 2024 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Feb 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 21, 2024 | Insider trade | SEC |
| 8-K · Current report | Feb 14, 2024 | Current report | SEC |
| 424B5 · Prospectus | Feb 14, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Feb 13, 2024 | Offer document | SEC |
This page holds 200 of 465 filings. Open Filings
Cap table
Built by 6ix from Immunome, Inc.’s releases · as of Nov 4, 2026
- Common shares
- 118,072,943
- Fully diluted
- 118,382,993
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 118,072,943 | Nov 4, 2026 |
| Options and RSUs | 310,050 | Nov 2, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · US$19.59 · expiry not stated |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 4, 2026 | 118,072,943 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Richard F Fitzgerald Other companies: 22nd Century Group, Inc (Chief Financial Officer · Nov 15, 2021 – Mar 21, 2022 · Past); Nauticus Robotics, Inc. (Chief Financial Officer · Jul 14, 2021 – Jul 14, 2021 · Past); Sesen Bio Inc (Chief Financial Officer · Feb 21, 2019 – Feb 21, 2019 · Past); Eleven Biotherapeutics Inc (Chief Financial Officer · Oct 20, 2017 – Apr 9, 2018 · Past); PAVmed Inc. (CFO and Secretary · Jan 29, 2016 – Jun 1, 2016 · Past); TechPrecision Corporation (Chief Financial Officer · Jun 13, 2013 – Aug 12, 2015 · Past) | Chief Financial Officer · Oct 1, 2020 – Oct 1, 2020 · Past |
| Carol A. Schafer Other companies: Kura Oncology, Inc. (Director · Since at least Jun 3, 2021); Repare Therapeutics Inc (Director · Since at least May 13, 2021); Insmed Incorporated (Director · Since at least May 12, 2021); Five Prime Therapeutics Inc (Director · Apr 16, 2021 – Apr 16, 2021 · Past); Aceragen Inc. (Director · Oct 1, 2020 – Jun 23, 2022 · Past) | Director · Since at least Jan 2, 2024 |
| John Higgins Other companies: OmniAb, Inc. (Board Chair · Since at least Nov 1, 2022); Bio-Techne Corp (Director · Since at least Jun 4, 2019); Ligand Pharmaceuticals Incorporated (Director · May 14, 2019 – Dec 28, 2022 · Past) | Chief Scientific Officer · Since at least Oct 2, 2023 |
| John L. LaMattina Other companies: Ligand Pharmaceuticals Incorporated (Director · Since at least May 31, 2012); Larimar Therapeutics, Inc. (Director · Jun 18, 2014 – Jun 26, 2019 · Past); Human Genome Sciences Inc (Director · May 17, 2012 – Jul 30, 2012 · Past) | Director · Oct 1, 2020 – Jun 8, 2023 · Past |
| Corleen Roche Other companies: Iovance Biotherapeutics, Inc. (Chief Financial Officer · Since at least Jul 15, 2025); CG Oncology, Inc. (CFO · Jan 24, 2024 – Apr 15, 2025 · Past) | Chief Financial Officer · Apr 19, 2021 – Jun 8, 2023 · Past |
| Clay Siegall Other companies: Shattuck Labs, Inc. (President, Chairman of the Board of Immunome, Inc. · Since at least Jun 11, 2026) | President & Chief Executive Officer · Since at least Jul 27, 2026 |
| Isaac Barchas Other companies: TMC The Metals Company Inc. (Director · May 5, 2020 – May 5, 2020 · Past) | Lead Independent Director and Director · Since at least Oct 2, 2023 |
| Philip Wagenheim Other companies: Swarmer, Inc (Director · Since at least Mar 16, 2026) | Director · Since at least Jun 10, 2025 |
| Richard A Baron Other companies: Zynerba Pharmaceuticals Inc (Chief Financial Officer · Aug 4, 2015 – Sep 11, 2015 · Past) | Director · Oct 1, 2020 – Jun 8, 2023 · Past |
| Bob Lechleider | Chief Medical Officer · Since at least Jul 27, 2026 |
All 25 people
| Person | Seat |
|---|---|
| Dennis H Giesing | Chief Development Officer · Mar 23, 2021 – Jun 8, 2023 · Past |
| Jack Higgins | Chief Scientific Officer · Since at least Oct 23, 2025 |
| James Boylan | Director · Since at least Nov 5, 2026 |
| Kinney Horn | CHIEF BUSINESS OFFICER · Since at least Jul 7, 2026 |
| Max Rosett | Chief Financial Officer · Since at least Oct 2, 2023 |
| Max Rosett | Chief Financial Officer · Since at least Jul 27, 2026 |
| Michael Lefenfeld | Director · Oct 1, 2020 – Jun 8, 2023 · Past |
| Michael Rapp | Director · Oct 1, 2020 – Oct 2, 2023 · Past |
| Philip Tsai | Chief Technical Officer · Since at least Jun 17, 2024 |
| Phil Tsai | Chief Technical Officer · Since at least Jul 27, 2026 |
| Purnanand D Sarma | President and CEO, Director · Oct 1, 2020 – Jun 8, 2023 · Past |
| Robert Lechleider | Chief Medical Officer · Since at least Oct 16, 2023 |
| Roee Shahar | EVP, Commercial · Since at least Nov 5, 2026 |
| Sandra M. Swain | Director · Since at least Nov 5, 2026 |
| Sandra Stoneman | CHIEF LEGAL OFFICER & GC · Since at least Oct 26, 2020 |
Log in to ask 6ix AI your own questions about Immunome, Inc.